Analyst Rating Update on BioDelivery Sciences International (BDSI)

BioDelivery Sciences International (NASDAQ:BDSI) has an average broker rating of 1.57, which is interpreted as a Buy, as rated by 7 equity analysts. Nonetheless, 5 analysts are positive on the stocks future and they recommend a Strong Buy on the stock. Nevertheless, the majority of 2 analysts consider that the stock is a Hold with neither a large upside nor a downside. Ranking by Zacks Investment Research for Coach Inc is 3, which is also a Hold.

BioDelivery Sciences International (NASDAQ:BDSI) : Currently there are 7 street experts covering BioDelivery Sciences International (NASDAQ:BDSI) stock. The most bullish and bearish price target for the stock is $16 and $4 respectively for the short term. The average price target of all the analysts comes to $7.43. The estimated standard deviation from the target is $4.2.

For the current week, the company shares have a recommendation consensus of Buy.

BioDelivery Sciences International (NASDAQ:BDSI): stock turned positive on Tuesday. Though the stock opened at $2.26, the bulls momentum made the stock top out at $2.48 level for the day. The stock recorded a low of $2.26 and closed the trading day at $2.35, in the green by 3.52%. The total traded volume for the day was 704,175. The stock had closed at $2.27 in the previous days trading.

In an insider trading activity, Bramlage Charles, director of Biodelivery Sciences International Inc, executed a transaction worth $24,957 on March 21, 2016. A total of 8,850 shares were purchased at an average price of $2.82. The Insider information was divulged by the Securities and Exchange Commission in a Form 4 filing. The information is based on open market trades at the market prices.Option exercises are not covered.

BioDelivery Sciences International, Inc. is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction. The Companys products and certain of its product candidates utilize the BioErodible MucoAdhesive (BEMA) drug delivery technology, a small, erodible polymer film for application to the buccal mucosa (the lining inside the cheek). The Companys United Sates Food and Drug Administration (FDA) approved product, ONSOLIS (fentanyl buccal soluble film), as well as its approved product BUNAVAIL (buprenorphine and naloxone buccal film) and its product candidate, BELBUCA utilize its BEMA technology.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.